EHA 2017 | The potential of momelotinib against myeloproliferative malignancies
Anemia remains an important, unsolved problem for patients suffering from myeloproliferative malignancies. Claire Harrison, MD, DM, FRCP, FRCPath from Guys and St Thomas’ NHS Foundation Trust, London, UK speaks to us about the potential importance of the drug momelotinib. Prof. Harrison discusses the interesting results of the Phase III clinical trials, SIMPLIFY 1 (NCT01969838) and 2 (NCT02101268) which compared momelotinib against ruxolitinib and Best Alternative Therapy. She also talks about her hopes for this drug in the future. This interview was recorded at the European Hematology Association (EHA) 2017 annual congress held in Madrid, Spain.
Get great new content delivered to your inboxSign up